$-0.03
(Market cap
$0 Mln
Recently Viewed
Clear AllMarket cap
$0 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
0.1
Div. Yield
0 %
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
$-16 Mln
ROE
-1.1 %
ROCE
-- %
Industry P/E
--
EV/EBITDA
0.2
Debt to Equity
0.1
Book Value
$4.2
EPS
$-3.9
Face value
--
Shares outstanding
4,872,497
CFO
$-416.08 Mln
EBITDA
$-430.89 Mln
Net Profit
$-543.11 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Calithera Biosciences (CALA)
| -- | -- | -- | -- | -80.4 | -90.7 | -72.4 |
|
BSE Sensex
| -9.5 | 5.5 | -6.0 | -4.3 | 8.7 | 9.9 | 11.5 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2021
|
2020
|
2019
|
2018
|
2017
|
2016
|
2015
|
|---|---|---|---|---|---|---|---|
|
Calithera Biosciences (CALA)
| -86.5 | -14.0 | 42.4 | -51.8 | 156.9 | -57.6 | -62.1 |
|
S&P Small-Cap 600
| 25.3 | 9.6 | 20.9 | -9.7 | 11.7 | 24.7 | -3.4 |
|
BSE Sensex
| 22.0 | 15.8 | 14.4 | 5.9 | 27.9 | 1.9 | -5.0 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Calithera Biosciences (CALA)
|
0.0 | 0.0 | 0.0 | -18.9 | -- | -131.1 | -- | 0.1 |
| 12.5 | 3,993.9 | 2,323.3 | 44.1 | 12.3 | -- | 56.9 | 105.4 | |
| 40.9 | 5,233.8 | 1,003.8 | 22.4 | 6.8 | 7.5 | 227.4 | 14.1 | |
| 186.0 | 9,512.5 | 638.5 | -183.2 | -27.4 | -252.1 | -- | 107.7 | |
| 73.3 | 14,206.3 | 502.1 | -729.3 | -125.8 | 41.2 | -- | 123.7 | |
| 46.1 | 4,944.9 | 761.4 | 99.7 | 7.3 | 15 | 56.2 | 7.6 | |
| 22.8 | 11,181.1 | 4,715.0 | -232.0 | 0.9 | -3.7 | -- | 1.7 | |
| 231.3 | 4,634.3 | 268.1 | 124.5 | 60.0 | 13.5 | 37.7 | 4.6 | |
| 37.3 | 3,287.6 | 158.3 | -68.9 | -29.3 | -113 | -- | 73.8 | |
| 60.9 | 3,736.3 | 391.6 | -76.6 | -19.3 | -16.4 | -- | 8.2 |
Calithera Biosciences, Inc. operates under a plan of liquidation that was approved in January 2023. Previously, the company was engaged in the clinical stage precision oncology biopharmaceutical business. Calithera Biosciences, Inc. was incorporated... in 2010 and is headquartered in South San Francisco, California. Read more
CFO & Secretary
Ms. Stephanie Wong
Senior Vice President of Development
Dr. Christopher J. Molineaux Ph.D.
Headquarters
South San Francisco, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Calithera Biosciences Inc (CALA) is $0.00 (NASDAQ) as of 24-Apr-2026 09:30 EDT. Calithera Biosciences Inc (CALA) has given a return of -80.43% in the last 3 years.
Since, TTM earnings of Calithera Biosciences Inc (CALA) is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2022
|
-0.84
|
0.78
|
|
2021
|
-0.02
|
0.30
|
|
2020
|
-0.20
|
0.17
|
|
2019
|
-0.18
|
0.11
|
|
2018
|
-0.15
|
0.06
|
The 52-week high and low of Calithera Biosciences Inc (CALA) are Rs 0.00 and Rs 0.00 as of 26-Apr-2026.
Calithera Biosciences Inc (CALA) has a market capitalisation of $ 0 Mln as on 24-Apr-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Calithera Biosciences Inc (CALA), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.